Europe Epigenetics Diagnostic Market, By Product (Reagents, Kits, Instruments & Consumables, Bioinformatics Tools & Enzymes), Technology (DNA Methylation, Histone Methylation, Chromatin Structures, Histone Acetylation, Large Non-Coding RNA & MicroRNA Modification), Type of Therapy (Histone Deacetylase (HDAC) Inhibitors, DNA Methyltransferase (DNMT) Inhibitors & Others), Application (Oncology, Cardiovascular Diseases, Metabolic Diseases, Immunology, Inflammatory Diseases, Infectious Diseases & Others), End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs) & Others), Distribution Channel (Direct Tender & Retail Sales), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland’s, Rest of Europe) Industry Trends and Forecast to 2028.
Market Analysis and Insights: Europe Epigenetics Diagnostic Market
Europe epigenetics diagnostic market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 12.7% in the forecast period of 2021 to 2028 and is expected to reach USD 3,268.01 million by 2028 from USD 1,292.28 million in 2020. The high prevalence of chronic diseases and high demand of epigenetics diagnosis for its effective application is likely to be the major drivers which propel the demand of the market in the forecast period.
The epigenetics diagnostic is the study of genetics, cellular and physical trait variations and developmental biology which is caused by the external environmental. This in turn affects genes and cellular ability to read genes without being affected by changes in genotype. The epigenetics changes result into changes in phenotype of organism rather than genotype, the underlying DNA and RNA sequence remains unchanged. The epigenetic changes are essential for development as they are dynamic and change with respect to environment.
The genetic expressions of organism are effected by epigenetics, which is making it the most crucial field of molecular biology and developmental genetics. Organizations, such as the National Center Institute, the National Institute of Health, and the International Human Epigenome Consortium, are funding and supporting research and development activities pertaining to the field of epigenetics. Epigenetics is also used to treat a variety of chronic diseases such as cancer, metabolic diseases, and others.
The Europe epigenetics diagnostic market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Europe Epigenetics Diagnostic Market Scope and Market Size
Europe epigenetics diagnostic market is categorized into six notable segments which are based on product, technology, type of therapy, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product, the Europe epigenetics diagnostic market is segmented into reagents, kits, instruments & consumables, bioinformatics tools, and enzymes. In 2021, reagents segment is expected to dominate the market as reagents are mostly being used in the field of diagnosis.
- On the basis of technology, the Europe epigenetics diagnostic market is segmented into DNA methylation, histone methylation, chromatin structures, histone acetylation, large non-coding RNA, and microRNA modification. In 2021, DNA methylation segment is expected to dominate the market as the DNA methylation technology is being used in a variety of epigenetics diagnosis.
- On the basis of type of therapy, the Europe epigenetics diagnostic market is segmented into histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, and others. In 2021, histone deacetylase (HDAC) inhibitors segment is expected to dominate the market as it plays a major role in several biological processes, such as proliferation, cell cycle progression and differentiation. Histone deacetylase (HDAC) and their inhibitors can be used to post-translationally modify histones—the histone code that is read and recognized by other proteins to regulate gene expression.
- On the basis of application, the Europe epigenetics diagnostic market is segmented into oncology, cardiovascular diseases, metabolic diseases, immunology, inflammatory diseases, and others. In 2021, oncology segment is expected to dominate the market as epigenetics diagnosis is used to diagnose various cancer.
- On the basis of end user, the Europe epigenetics diagnostic market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others. In 2021, academic and research institutes segment is expected to dominate the market as research institutes perform an essential role to accelerate research and development in various therapeutic areas related to epigenetics diagnosis.
- On the basis of distribution channel, the Europe epigenetics diagnostic market is segmented into direct tender and retail sales. In 2021, direct tender segment is expected to dominate the market due to escalation in marketing activities and improved customer services.
Europe Epigenetics Diagnostic Market Country Level Analysis
Europe epigenetics diagnostic market is analysed, and market size information is provided by product, technology, type of therapy, application, end user, and distribution channel.
The countries covered in the Europe epigenetics diagnostic market report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe
Germany is expected to grow in Europe epigenetics diagnostic market, due to the prevalence of cancer, people are getting more aware towards early diagnosis, and increasing healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities In The Europe Epigenetics Diagnostic Market
Europe epigenetics diagnostic market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the epigenetics diagnostic market. The data is available for the historic period 2010 to 2019.
Competitive Landscape and Europe Epigenetics Diagnostic Market Share Analysis
Europe epigenetics diagnostic market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to dental instruments market.
Some of the major companies providing the epigenetics diagnostic are PerkinElmer Inc., Diagenode, F. Hoffman-La Roche Ltd, EPICYPHER, Cambridge Epigenetix (CEGX), Promega Corporation, QIAGEN, Pacific Biosciences of California, Inc., Epigenomics AG, Mnemo, Reaction Biology, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Merck KGaA, Illumina, Inc., ACTIVEMOTIF, Thermo Fisher Scientific, Inc., EpiGentek Group Inc., Enzo Life Sciences, Inc., Epizyme, Inc., GlaxoSmithKline plc., Eclipse BioInnovations, MDxHealth, Abcam plc, Salarius Pharmaceuticals, Inc. and Datar Cancer Genetics among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players and new technological advancements for epigenetics diagnostic are bridging the gap for variety of treatments.
For instance,
- In May 2021, QIAGEN has entered into partnership with Mirati Therapeutics Inc. to develop KRAS-G12C companion diagnostic for Non-Small Cell Lung Cancer (NSCLC). KRAS mutations in NSCLC reflect a large underserved patient population with an unmet need for innovative treatment options. This helped QIAGEN to strengthen position in KRAS companion diagnostic testing in NSCLC.
Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the epigenetics diagnostic market, which also provides the benefit for the organization to improve their offering for epigenetics diagnostic market.
SKU-